Audentes Therapeutics Inc (NASDAQ:BOLD) has been assigned a consensus recommendation of “Buy” from the eighteen research firms that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $41.66.
A number of equities analysts have issued reports on BOLD shares. BidaskClub upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, February 23rd. ValuEngine upgraded shares of Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. Zacks Investment Research cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. HC Wainwright restated a “buy” rating and issued a $33.00 price objective on shares of Audentes Therapeutics in a research report on Friday, January 11th. Finally, Mizuho restated a “buy” rating and issued a $45.00 price objective on shares of Audentes Therapeutics in a research report on Friday, February 1st.
In related news, CEO Matthew R. Patterson sold 21,000 shares of the business’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $30.00, for a total transaction of $630,000.00. Following the sale, the chief executive officer now owns 135,700 shares of the company’s stock, valued at $4,071,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Suyash Prasad sold 10,000 shares of the business’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $30.06, for a total transaction of $300,600.00. Following the sale, the vice president now directly owns 28,236 shares in the company, valued at approximately $848,774.16. The disclosure for this sale can be found here. Insiders have sold a total of 51,000 shares of company stock worth $1,650,600 in the last ninety days. Insiders own 6.60% of the company’s stock.
Shares of BOLD stock traded up $0.74 during mid-day trading on Wednesday, reaching $37.79. The stock had a trading volume of 981,500 shares, compared to its average volume of 539,841. Audentes Therapeutics has a 52-week low of $17.95 and a 52-week high of $46.18. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -11.11 and a beta of 1.85.
Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). During the same quarter in the previous year, the firm posted ($0.74) EPS. On average, research analysts expect that Audentes Therapeutics will post -3.8 EPS for the current fiscal year.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
See Also: Put Option
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.